Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non‐Small Cell Lung Cancer

BACKGROUND. The VeriStrat test provides accurate predictions of outcomes in all lines of therapy for patients with non‐small cell lung cancer (NSCLC). We investigated the predictive and prognostic role of VeriStrat in patients enrolled on the MARQUEE phase III trial of tivantinib plus erlotinib (T+E...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Buttigliero, Consuelo, Shepherd, Frances A., Barlesi, Fabrice, Schwartz, Brian, Orlov, Sergey, Favaretto, Adolfo G., Santoro, Armando, Hirsh, Vera, Ramlau, Rodryg, Blackler, Adele R., Roder, Joanna, Spigel, David, Novello, Silvia, Akerley, Wallace, Scagliotti, Giorgio V.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2018
Schlagworte:
European Perspectives
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656491/
https://ncbi.nlm.nih.gov/pubmed/30139835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0089
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge